Clinical trials
Glucose Intolerance trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 11 |
| Completed | 5 |
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Huazhong University of Science and Technology | 2 |
| Shandong Provincial Hospital | 2 |
| Beijing Tongren Hospital | 1 |
| China-Japan Friendship Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| Chinese University of Hong Kong | 1 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| Haisco Pharmaceutical Group Co., Ltd. | 1 |
| Li Huating | 1 |
| Ministry of Science and Technology of the People´s Republic of China | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glucose Intolerance | 23 |
| Prediabetic State | 8 |
| Diabetes Mellitus, Type 2 | 6 |
| Diabetes Mellitus | 3 |
| Obesity | 3 |
| Coronary Disease | 2 |
| Overweight | 2 |
| Acute Coronary Syndrome | 1 |
| Cardiovascular Diseases | 1 |
| Hyperglycemia | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.